DCT and melanoma: Importantly, intradermal administration of a DNA vaccine encoding an SCT chimeric protein, containing tyrosinase-related protein 2 (Trp2), a melanoma antigen was able to elicit a powerful Trp2-specific CD8+ T cell-mediated immune response and suppress B16 tumor growth and spread in a murine model (95).